share_log

康寧傑瑞製藥-B：2023 環境、社會及管治報告

ALPHAMAB-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Hong Kong Stock Exchange ·  Apr 29 18:07
Summary by Futu AI
康寧杰瑞制藥-B（ALPHAMAB-B）於2023年發佈環境、社會及管治報告，涵蓋期間為2023年1月1日至12月31日。報告顯示，公司專注於抗腫瘤領域生物創新藥的發現、開發、生產和商業化，並於2019年12月12日在香港聯交所主板上市。公司秉持「康達病患、瑞濟萬家」的企業理念，努力開發下一代創新藥物。報告期內，公司積極推進環境管理體系建設，並在環境、社會及管治方面取得顯著進展。公司嚴格遵守相關法律法規，並通過多種形式與員工保持溝通，提供具有市場競爭力的薪酬和福利待遇，同時注重員工的職業發展和安全健康。此外，公司積極參與公益活動，推動普惠醫療和醫療科普，回饋社會。報告亦顯示，公司在知識產權保護方面表現出色，未發生侵犯他人知識產權的訴訟或糾紛事件。
康寧杰瑞制藥-B（ALPHAMAB-B）於2023年發佈環境、社會及管治報告，涵蓋期間為2023年1月1日至12月31日。報告顯示，公司專注於抗腫瘤領域生物創新藥的發現、開發、生產和商業化，並於2019年12月12日在香港聯交所主板上市。公司秉持「康達病患、瑞濟萬家」的企業理念，努力開發下一代創新藥物。報告期內，公司積極推進環境管理體系建設，並在環境、社會及管治方面取得顯著進展。公司嚴格遵守相關法律法規，並通過多種形式與員工保持溝通，提供具有市場競爭力的薪酬和福利待遇，同時注重員工的職業發展和安全健康。此外，公司積極參與公益活動，推動普惠醫療和醫療科普，回饋社會。報告亦顯示，公司在知識產權保護方面表現出色，未發生侵犯他人知識產權的訴訟或糾紛事件。
CORNINGER PHARMACEUTICAL-B (ALPHAMAB-B) PUBLISHED ITS ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT FOR 2023 COVERING THE PERIOD FROM JANUARY 1 TO DECEMBER 31, 2023. The report shows that the company focuses on the discovery, development, production and commercialization of bio-innovative drugs in the anti-tumor field and listed on the main board of the Hong Kong Stock Exchange on 12 December 2019. The company strives to develop the next generation of innovative medicines, following the corporate philosophy of “Patients of Condé and the Home of Ruizei”. During the reporting period, the company actively promoted the construction of environmental management systems and made significant progress in environmental, social and governance. The company strictly adheres to relevant laws and regulations and communicates with employees in a variety...Show More
CORNINGER PHARMACEUTICAL-B (ALPHAMAB-B) PUBLISHED ITS ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT FOR 2023 COVERING THE PERIOD FROM JANUARY 1 TO DECEMBER 31, 2023. The report shows that the company focuses on the discovery, development, production and commercialization of bio-innovative drugs in the anti-tumor field and listed on the main board of the Hong Kong Stock Exchange on 12 December 2019. The company strives to develop the next generation of innovative medicines, following the corporate philosophy of “Patients of Condé and the Home of Ruizei”. During the reporting period, the company actively promoted the construction of environmental management systems and made significant progress in environmental, social and governance. The company strictly adheres to relevant laws and regulations and communicates with employees in a variety of forms, providing market-competitive pay and benefits treatment, while focusing on the professional development and safe health of employees. In addition, the company actively participates in public welfare activities, promotes universal health and medical sciences, and gives back to society. The report also shows that the company has performed well in terms of intellectual property protection and there have been no lawsuits or disputes that infringe the intellectual property rights of others.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.